辰光医疗
(430300)
| 流通市值：5.14亿 | | | 总市值：7.34亿 |
| 流通股本：6009.32万 | | | 总股本：8584.71万 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 20,859,112.75 | 165,644,428.37 | 99,477,600.49 | 56,084,453.17 |
| 营业收入 | 20,859,112.75 | 165,644,428.37 | 99,477,600.49 | 56,084,453.17 |
| 二、营业总成本 | 30,698,379.49 | 179,395,354.49 | 114,273,918.71 | 65,020,440.66 |
| 营业成本 | 10,186,735.54 | 107,650,908.52 | 63,601,999 | 34,113,867.67 |
| 税金及附加 | 359,154.3 | 1,896,394.58 | 1,275,963.53 | 706,970.38 |
| 销售费用 | 7,432,956.77 | 18,946,206.29 | 14,462,482.76 | 7,974,812.82 |
| 管理费用 | 5,762,963.22 | 27,464,920.06 | 21,089,421.39 | 14,470,293.33 |
| 研发费用 | 6,033,462.71 | 20,049,634.39 | 11,738,080.02 | 6,663,957.33 |
| 财务费用 | 923,106.95 | 3,387,290.65 | 2,105,972.01 | 1,090,539.13 |
| 其中:利息费用 | 1,163,114.31 | 3,697,146.36 | 2,815,447.16 | 1,706,849.44 |
| 其中:利息收入 | 103,506.75 | 525,141.1 | 523,897.15 | 435,466.52 |
| 加:投资收益 | 373.8 | 619,038.77 | 171,753.26 | 171,753.26 |
| 资产处置收益 | - | -996,326.93 | -928,093.47 | -929,509.61 |
| 资产减值损失(新) | - | -1,886,605.37 | 71,385.45 | 71,385.45 |
| 信用减值损失(新) | - | -9,616,774.42 | 75,815.88 | 75,815.88 |
| 其他收益 | 646,611.07 | 6,040,733.76 | 3,679,681.84 | 2,637,011.28 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -9,192,281.87 | -19,590,860.31 | -11,725,775.26 | -6,909,531.23 |
| 加:营业外收入 | 145,438.02 | 3,000,050.86 | 3,025,450.9 | 3,021,450.38 |
| 减:营业外支出 | 227 | 145,992.11 | 115,872.11 | 100,726.01 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -9,047,070.85 | -16,736,801.56 | -8,816,196.47 | -3,988,806.86 |
| 减:所得税费用 | 8,394.22 | -4,232,425.44 | -1,906,956.3 | -944,024.19 |
| 六、净利润 | -9,055,465.07 | -12,504,376.12 | -6,909,240.17 | -3,044,782.67 |
| 持续经营净利润 | -9,055,465.07 | -12,504,376.12 | -6,909,240.17 | - |
| 归属于母公司股东的净利润 | -9,055,465.07 | -11,782,726.74 | -6,909,240.17 | -2,658,811.01 |
| 少数股东损益 | - | -721,649.38 | - | -385,971.66 |
| (一)基本每股收益 | -0.11 | -0.14 | -0.08 | -0.03 |
| (二)稀释每股收益 | -0.11 | -0.14 | -0.08 | -0.03 |
| 九、综合收益总额 | -9,055,465.07 | -12,504,376.12 | -6,909,240.17 | -3,044,782.67 |
| 归属于母公司股东的综合收益总额 | -9,055,465.07 | -11,782,726.74 | -6,909,240.17 | -2,658,811.01 |
| 归属于少数股东的综合收益总额 | - | -721,649.38 | - | -385,971.66 |
| 公告日期 | 2024-04-26 | 2024-04-23 | 2023-10-30 | 2023-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |